RCB-185 Small Molecule Targeting Dxr Enzyme for Drug-Resistant Malaria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial therapies face challenges due to pervasive drug resistance and limited new drug targets, with artemisinin combination therapies becoming less effective, necessitating the identification of novel targets in the methylerythritol phosphate pathway of Plasmodium falciparum.
Innovation Solution
Development of a small molecule, RCB-185, which targets the deoxyxylulose phosphate reductoisomerase (Dxr) enzyme in the MEP pathway, inhibiting its function and effectively reducing isoprenoid biosynthesis in P. falciparum, thereby treating or preventing malaria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin combination therapies (ACTs) are used to treat P. falciparum malaria, then treatment effectiveness is initially maintained, but drug resistance develops over time causing effectiveness to wane
Solution Approach 1:
The patent targets a specific enzyme (Dxr) in the MEP pathway of P. falciparum, segmenting the treatment approach from broad-spectrum artemisinins to a precisely targeted mechanism. This enzyme-specific inhibition addresses drug resistance by attacking a different biological pathway rather than relying on the deteriorating ACT mechanism
Solution Approach 2:
The compound changes the therapeutic parameter from iron-chelating heme disruption (artemisinins) to enzymatic inhibition of isoprenoid biosynthesis (MEP pathway). This parameter shift allows treatment of strains resistant to artemisinins while maintaining effectiveness against P. falciparum
2Reliability
If fosmidomycin is used to inhibit Dxr enzyme, then antimalarial activity is achieved, but potency is limited requiring higher doses
Solution Approach 1:
The patent modifies the chemical parameters of Dxr inhibitors by developing a novel compound structure (RCB-185) with different pharmacological properties than fosmidomycin. This structural parameter change results in 50-fold increased potency while maintaining the same enzymatic target and mechanism of action
Solution Approach 2:
The compound combines multiple structural features including a fluorinated phenyl group, pyrimidine ring, and specific substituent patterns that create a composite molecular structure with optimized binding affinity to Dxr, achieving superior potency compared to fosmidomycin
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
RCB-185 demonstrates potent activity against drug-resistant P. falciparum strains, safely treating malaria-infected mice and showing a 50-fold higher potency than fosmidomycin, with a unique binding mode that maintains safety and efficacy, indicating its potential as a lead antimalarial compound.
Implementation Method 1
The small molecule inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway
Data Source
AI summary
A pharmaceutical composition includes a small molecule and a pharmaceutically acceptable excipient. The small molecule interacts with a deoxyxylulose phosphate reductoisomerase (Dxr). A method for treating or preventing a microbial infection in a subject in need thereof includes administering the pharmaceutical composition. A method for inhibiting the growth of a eukaryotic pathogen includes contacting the eukaryotic pathogen with an effective amount of the pharmaceutical composition.